Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcinosis | 4 | 2006 | 170 | 0.580 |
Why?
|
| Breast Neoplasms | 5 | 2006 | 2476 | 0.470 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2006 | 23 | 0.320 |
Why?
|
| Neck Dissection | 1 | 2007 | 18 | 0.280 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 39 | 0.270 |
Why?
|
| Bacterial Infections | 2 | 2006 | 305 | 0.260 |
Why?
|
| Magnesium Deficiency | 1 | 2005 | 10 | 0.260 |
Why?
|
| Glucuronidase | 1 | 2005 | 31 | 0.260 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 197 | 0.260 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 48 | 0.260 |
Why?
|
| Kv1.3 Potassium Channel | 2 | 2017 | 36 | 0.250 |
Why?
|
| Magnesium | 1 | 2005 | 121 | 0.250 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 133 | 0.250 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 75 | 0.240 |
Why?
|
| Antineoplastic Agents | 5 | 2006 | 1661 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2005 | 84 | 0.240 |
Why?
|
| Osteoporosis | 1 | 2005 | 114 | 0.240 |
Why?
|
| ErbB Receptors | 1 | 2005 | 284 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 321 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 180 | 0.220 |
Why?
|
| Th2 Cells | 2 | 2014 | 187 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 1010 | 0.210 |
Why?
|
| Estrogens | 1 | 2005 | 507 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 481 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 427 | 0.190 |
Why?
|
| Anticoagulants | 1 | 2005 | 582 | 0.180 |
Why?
|
| Potassium Channel Blockers | 2 | 2017 | 84 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1227 | 0.160 |
Why?
|
| Stroke | 1 | 2007 | 958 | 0.160 |
Why?
|
| Scorpion Venoms | 1 | 2017 | 13 | 0.140 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 169 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 935 | 0.140 |
Why?
|
| Asthma | 2 | 2014 | 745 | 0.130 |
Why?
|
| Breast Diseases | 2 | 2006 | 34 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 217 | 0.130 |
Why?
|
| Diphosphonates | 2 | 2005 | 37 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 1308 | 0.120 |
Why?
|
| Peptides | 1 | 2017 | 794 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 650 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 225 | 0.100 |
Why?
|
| Bacteria | 2 | 2006 | 482 | 0.100 |
Why?
|
| Neoplasms | 1 | 2005 | 2758 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 597 | 0.090 |
Why?
|
| Humans | 18 | 2017 | 123213 | 0.080 |
Why?
|
| Chemokine CXCL12 | 2 | 2006 | 33 | 0.080 |
Why?
|
| Quality of Life | 1 | 2017 | 1932 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3084 | 0.070 |
Why?
|
| Cetuximab | 1 | 2005 | 12 | 0.070 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2005 | 13 | 0.070 |
Why?
|
| Bridged-Ring Compounds | 1 | 2005 | 17 | 0.060 |
Why?
|
| Female | 10 | 2017 | 65516 | 0.060 |
Why?
|
| Hyponatremia | 1 | 2007 | 70 | 0.060 |
Why?
|
| Nanostructures | 1 | 2006 | 52 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2005 | 35 | 0.060 |
Why?
|
| Taxoids | 1 | 2005 | 65 | 0.060 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2005 | 24 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 49 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2017 | 318 | 0.060 |
Why?
|
| Chemokines | 1 | 2005 | 137 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2005 | 490 | 0.060 |
Why?
|
| Mammography | 1 | 2005 | 113 | 0.060 |
Why?
|
| Quinazolines | 1 | 2005 | 175 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 211 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 274 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 137 | 0.060 |
Why?
|
| Ligands | 1 | 2005 | 533 | 0.060 |
Why?
|
| Breast | 1 | 2005 | 214 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 2840 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4276 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2007 | 747 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 572 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 332 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 1472 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2007 | 762 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2108 | 0.040 |
Why?
|
| Rats | 2 | 2017 | 3654 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 3047 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12134 | 0.040 |
Why?
|
| Arthritis, Experimental | 1 | 2017 | 15 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2017 | 33 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 2017 | 68 | 0.040 |
Why?
|
| Terpenes | 1 | 2017 | 28 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1676 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 424 | 0.030 |
Why?
|
| Biomarkers | 2 | 2017 | 2945 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 81 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 1232 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 272 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 2802 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1582 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 325 | 0.030 |
Why?
|
| Allergens | 1 | 2017 | 245 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 26009 | 0.030 |
Why?
|
| Arteries | 2 | 2007 | 222 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1243 | 0.030 |
Why?
|
| Animals | 3 | 2017 | 33761 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2014 | 44 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 105 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 254 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2014 | 138 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1310 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2014 | 96 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 159 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 171 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 180 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1997 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1496 | 0.030 |
Why?
|
| Biological Products | 1 | 2014 | 113 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2773 | 0.020 |
Why?
|
| Young Adult | 2 | 2017 | 8886 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 803 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 317 | 0.020 |
Why?
|
| Risk Factors | 1 | 2005 | 10015 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2405 | 0.020 |
Why?
|
| Aged | 3 | 2017 | 19089 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 29091 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4507 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3328 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 4705 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2007 | 75 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 144 | 0.020 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2005 | 3 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 291 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2005 | 131 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 52 | 0.020 |
Why?
|
| Postmenopause | 1 | 2005 | 125 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2005 | 135 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 141 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 119 | 0.010 |
Why?
|
| Heart Valves | 1 | 2005 | 51 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 354 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 338 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 4227 | 0.010 |
Why?
|
| Male | 3 | 2017 | 60117 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1388 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1096 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 17496 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 16019 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2962 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 6373 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 19124 | 0.000 |
Why?
|